OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Real-time Boerse Frankfurt Warrants 11:54:36 2024-05-02 EDT | ||
| 5.79 EUR | +1.40% |
|
| 1 month | +36.93% | ||
| 3 months | +41.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 5.79 | +1.40% | 0 |
| 24-04-30 | 5.71 | +1.24% | 0 |
| 24-04-29 | 5.64 | -1.05% | 0 |
| 24-04-26 | 5.7 | +1.42% | 0 |
| 24-04-25 | 5.62 | +15.40% | 0 |
Real-time Boerse Frankfurt Warrants
Last update May 02, 2024 at 11:54 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | CL9B41 |
| ISIN | DE000CL9B417 |
| Date issued | 2020-04-07 |
| Strike | 7,165 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.36 € |
|---|---|
| Lowest since issue | 0.53 € |
| Spread | 0.07 € |
| Spread % | 1.19% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
152
USD
Average target price
164.3
USD
Spread / Average Target
+8.09%
- Stock Market
- Certificates
- Certificat
